Pubblicazioni

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

2024 - LEUKEMIA
Cortes, Jorge E.; Sasaki, Koji; Kim, Dong-Wook; Hughes, Timothy P.; Etienne, Gabriel; Mauro, Michael J.; Hochhaus, Andreas; Lang, Fabian; Heinrich, Michael C.; Breccia, Massimo; Deininger, Michael; Goh, Yeow Tee; Janssen, Jeroen J. W. M.; Talpaz, Moshe; de Soria, Valle Gomez Garcia; le Coutre, Philipp; Deangelo, Daniel J.; Damon, Andrea; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Rea, Delphine

CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

2022 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Hughes, Timothy P.; Cortes, Jorge E.; Réa, Delphine; Mauro, Michael J.; Hochhaus, Andreas; Kim, Dong-Wook; Sasaki, Koji; Lang, Fabian; Heinrich, Michael C.; Breccia, Massimo; Deininger, Michael; Goh, Yeow-Tee; Janssen, Jeroen J. W. M; Talpaz, Moshe; Coutre, Philipp le; Kapoor, Shruti; Cacciatore, Silvia; Polydoros, Fotis; Agrawal, Nithya; Mahon, Francois-Xavier

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma